Receive AXLA Stock News and Ratings via Email, November 6, 2022|americanbankingnews.com, November 4, 2022|markets.businessinsider.com, November 4, 2022|americanbankingnews.com, November 3, 2022|americanbankingnews.com, September 6, 2022|markets.businessinsider.com. We believe that if we can harness the full potential of our people, we can transform the lives of people and patients worldwide. Export data to Excel for your own analysis. Axcella Health has only been the subject of 3 research reports in the past 90 days. The financing occurred at a market price of $1.64, and the company sold 20,847,888 shares of common stock to a combination of current investors, new investors, company directors, and management. So, operator, this concludes our call. How were Axcella Health's earnings last quarter? View our AXLA earnings forecast. The CEO is very down to earth and quality-minded. One of the major owners of Axcella Health ( NASDAQ:AXLA) engaged in a huge insider buy transaction yesterday. So, we are - as you know, we've recently raised in the register direct, $34.2 million. [Operator instructions]. Axcella Health Careers and Employment. All Axcellans are eligible for stock option awards and the opportunity to participate in an employee stock purchase plan. It's a pleasure to be speaking with you again. While the stock has lost 8.8% over the past week, it could witness a trend re. The company has a debt-to-equity ratio of 2.33, a current ratio of 2.69 and a quick ratio of 2.69. Axcella Health Inc. operates as a clinical stage biotechnology company in the United States. Thank you again for taking questions and looking forward to progress on both programs. The company entered into a securities purchase agreement with investors to offer 20,847,888 shares of common stock at a purchase price of $1.64 per share. This week, the Dow Jones Industrial Average fell 0.3%, and the S&P 500 fell 0.7%. Now, in general rule, we don't comment on details of regulatory interactions. We are proud to have signed MassBios Open Letter 2.0 The CEO Pledge for a More Equitable & Inclusive Life Sciences Industry. Stock update. However, the shares have given back most. Axcella Health stock opened at $1.46 on Friday. Save my name, email, and website in this browser for the next time I comment. Facebook The company treats complex diseases and enhances health using endogenous metabolic modulator compositions. MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation. In-depth coverage of innovation, business, financing, regulation, science, product development, clinical trials and more Yes, we anticipate carrying forward the measurement of fatigue. The company earns $-64,630,000.00 in net income (profit) each year or ($1.66) on an earnings per share basis. Posted by Defense World Staff on Oct 22nd, 2022. The company treats complex diseases and enhances health using endogenous metabolic modulator compositions. MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Print. Thank you for the additional details. What is Axcella Health's stock price forecast for 2023? Based on an average trading volume of 162,700 shares, the short-interest ratio is currently 1.5 days. Get the latest business insights from Dun & Bradstreet. The stock has a fifty day moving average price of . Yes, Thomas. We also contribute directly to a Healthcare Reimbursement Account, provide short- and long-term disability benefits, and offer the choice to enroll in a Flexible Savings Account. Chart AXCELLA HEALTH INC. We've invited our clients Epizyme Axcella Health and Ironwood Pharmaceuticals to share what their business case for moving to Workday Adaptive Planning looked like and the key components to . Got it. It engages in the research and development of treatment for diseases and improves health using endogenous metabolic modulator, or EMM, and. Long-term financial health is important to all Axcellans, which is why we offer a 401k plan that matches 50% up to the first 6% of our employee's contribution in addition to Life Insurance. See Top Rated MarketRank Stocks Here About Axcella Health (NASDAQ:AXLA) Stock Berenberg Bank Initiates Coverage on Rapid7 (NASDAQ:RPD), Alfred Lee Finley Acquires 50,000 Shares of Medalist Diversified REIT, Inc. (NASDAQ:MDRR) Stock, Get a free copy of the StockNews.com research report on Axcella Health (AXLA). Good morning, this is (indiscernible) on for Tom Smith. According to analysts' consensus price target of $6.25, Axcella Health has a forecasted upside of 602.2% from its current price of $0.89. We act with urgency to advance our product candidates. Thank you, operator, and thanks everyone who tuned in today. This is an objective measure of physical ability that was only observed in subjects who received AXA1125. The stock has a fifty day moving average price of $2.01 and a two-hundred day moving average price of $2.00. This is Thomas Yip asking a couple of questions for Ed. Complex diseases require a multi-targeted approach. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Receive News & Ratings for Axcella Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axcella Health and related companies with MarketBeat.com's FREE daily email newsletter. Real-time analyst ratings, insider transactions, earnings data, and more. This compares to $4.8 million and $14 million for the same periods of 2021. We will, of course, look at the optimal way strategically, as Bob alluded to, as to how we can either accelerate or expand our ability to reach more patients faster. Financial Statements. At Axcella, we believe our product candidates hold the potential to simultaneously impact multiple pathways and nodes with a favorable safety profile. And on September 29, we reported results of a pre-planned interim analysis of data from our Phase 2b trial of AXA1125 in the treatment of Non-Alcoholic Steatohepatitis or NASH. , Axcella Health Inc's quarterly earnings growth was a positive 0% while revenue growth was a positive 0% . Earnings for Axcella Health are expected to grow in the coming year, from ($1.39) to ($1.05) per share. founded by flagship pioneering in 2009, axcella is a biotechnology company pioneering a new way to harness the power of endogenous metabolic modulators, or emms, with the goals of reprogramming metabolism and restoring metabolic health to treat a broad range of complex diseases and health conditions in ways that are simply not possible with We believe each Axcellan is critical to realizing the promise of our vision and achieving our strategy. This requires relentless focus, prioritization and the willingness to make smart trade-off decisions by considering quality, speed and risk. 4 people found this review helpful. We believe there's blockbuster potential in the United States. 51-200 Employees; Based in Cambridge, Massachusetts; Axcella is a clinical-stage biotechnology company focused on leveraging endogenous metabolic modulators (EMMs) to pioneer a new approach for treating complex diseases and improving health. On average, they expect the company's share price to reach $6.25 in the next twelve months. Axcella corporate office is located in 840 Memorial Dr Fl 3, Cambridge, Massachusetts, 02139, United States and has 97 employees. There are currently 5 buy ratings for the stock. Please go ahead. Time Off Following the completion of the sale, the chief executive officer now directly owns 82,012 shares of the companys stock, valued at $127,938.72. Helpful. Given the COVID trial results, 1125 has become the first therapeutic to improve patient fatigue in a randomized trial. Got it. So, we set out to develop AXA1125 to offer treatment options to seriously ill long COVID patients who previously had none. What is Bill Hinshaw's approval rating as Axcella Health's CEO? Got it. So, what's your strategy to alleviate the financing overhang in 2023? Please go ahead, sir. Axcella Health formerly known as Pronutria biotechnology company focuses on research and development of novel multifactorial interventions to support health and Read More Phone Number: (857) 320-2200 Website: www.axcellahealth.com Revenue: $14 Million Axcella's Social Media Is this data correct? Whether you drive or use public transportation, we provide the financial support for your travels. Analyst Forecast . Axcella Health, Inc. is a biotechnology company, which engages in the research and development of novel multifactorial interventions to support health and address dysregulated metabolism across a broad spectrum of consumers and patients who have limited options. Please be advised that todays call is being recorded, and that all participants will be in a listen-only mode until the question-and-answer session. One share of AXLA stock can currently be purchased for approximately $0.90. So, we've demonstrated our ability to execute on that scale. Instead, our . For Axcella Health profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Axcella Health to generate income relative to revenue, assets, operating costs, and current equity. . AXLA has been the subject of a number of analyst reports. Axcella Health Inc. is a clinical-stage biotechnology company focused on a new approach to treat complex diseases using compositions of endogenous metabolic modulators (EMMs). We also saw statistically significant improvements in ALT at both weeks 12 and 24 in all subjects. We would like to advise that certain remarks we will make on todays conference call, such as those relating to our cash runway and our ongoing clinical trials of AXA1125, include forward-looking statements that are subject to various risks and uncertainties. 840 Memorial Drive, 3rd Floor, Cambridge, MA 02139. We are certainly energized by the opportunity to help address the substantial needs of patients who have long COVID fatigue and NASH. We encourage our employees to openly share their learnings throughout the organization, so we can actively incorporate these insights into our work. Axcella Health (NASDAQ:AXLA) has a market capitalization of $47.27 million. Indeed, Time Magazine has described long COVID as the greatest mass disabling event in history. And until our study, no previous pharmaceutical agent had demonstrated the ability to improve outcomes for patients with long COVID in a randomized controlled trial. Bill? Employees: 49: Founded: 2008: Contact Information . Long COVID is a persistent and growing challenge of the pandemic, affecting an estimated 100 million patients worldwide, with fatigue as the most common symptom reported. The precise tool that we're using for that will be a discussion with the agency. These decreases are primarily the result of lower non-cash stock-based compensation expenses. Now, on August 2, we announced positive topline results from our Phase 2a study of AXA1125 in long COVID. Location: Cambridge, Massachusetts, United States . And consistent with prior clinical trials, Type 2 diabetics showed results comparable to non-diabetics. Join the Axcella Health team See Our Latest Jobs 5.0 Former Employee, more than 1 year Excellent ethical leadership and solid approach to the science and medicine Sep 13, 2021 - Anonymous Employee in Cambridge, MA Recommend CEO Approval Business Outlook Pros Good people running the show. Perhaps last question from us, switching to NASH, we saw the interim data was quite encouraging, but did not see better results in Type 2 diabetes patients as we did in the 16-week study. cambridge, mass., october 14, 2022--axcella therapeutics (nasdaq: axla), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endogenous. To see all exchange delays and terms of use please see Barchart's disclaimer. Axcella Health, Inc. Cambridge, MA. The company has deveveloped a systems pharmacology approach to address amino acid imbalances and restore health at the cellular level. Axcella Health Inc's PE and . The company has discovered more than 2,000 diseases with amino acid imbalances and developed a systems pharmacology approach to restore health at the cellular level. Based in the U.S., Axcella Health, Inc. is a biotechnology company that focuses on the research and . Axcella is committed to equal employment opportunity and non-discrimination for all employees and qualified applicants without regard to a persons race, color, gender, age, religion, national origin, ancestry, disability, veteran status, genetic information, sexual orientation or any characteristic protected under applicable law. Thats why Axcella covers 85% of employees medical, dental and vision benefits. Founded. Axcella Health's mailing address is 840 MEMORIAL DRIVE, CAMBRIDGE MA, 02139. As the company advances towards late-stage clinical trials, we are pleased to have the additions of Mr. Rosiello, and Mr. Straight Nissen, to our board. View our full suite of financial calendars and market data tables, all for free. These results were supported by statistically significant improvements in other non-invasive measures of liver fibrosis, ELF, and FIB four. High institutional ownership can be a signal of strong market trust in this company. Full Company Profile. Indeed, Time Magazine has described long COVID as the greatest mass disabling event in history. Spokesperson Catherine Falcetti. thank you. Nbr of Employees: 59: Free-Float: 76,2%: More Financials. These filings can be accessed on our website, axcellatx.com, or on the SEC website. On October 13, 2022, we announced a registered direct financing of approximately $34.2 million. MOST RECENT 2021 Annual Report and Form 10K. 5 employees have rated Axcella Health Chief Executive Officer Bill Hinshaw on Glassdoor.com. Going forward, I can assure you that what we'll be doing is what's in the best interest of the company and stakeholders as we go forward, although I can't offer any specifics at this time. A downtrend has been apparent in Axcella Health Inc. (AXLA) lately. View contact profiles from Axcella SIC Code 28,283 Axcella to Present at the American Association for the Study of Liver Diseases (AASLD) Annual Meeting. It engages in the research and development of treatment for diseases and improves health using endogenous metabolic modulator, or EMM, and compositions. Thank you, Bill, and good morning, everyone. The stocks traded within a . Bad management. Axcella Health Inc a biotechnology company involved in the research and development of novel multifactorial interventions to support health and address dysregulated metabolism. Through the third quarter, we made important progress in our clinical development of AXA1125, and strengthened our balance sheet with a new financing. Axcella Health, Inc. is a biotechnology company. The company is very young and it has already been through two rounds of layoffs . View which stocks are hot on social media with MarketBeat's trending stocks report. Axcella Health has received a consensus rating of Buy. The Companys product candidates are comprised of multiple EMMs that are engineered in distinct combinations and ratios with the goal of simultaneously impacting . Thank you, Bob, and good morning, everyone. This has been an extremely exciting period for Axcella, and today, I will briefly review the progress we've made during the past quarter. Got it. HC Wainwright increased their price objective on Axcella Health from $8.00 to $10.00 and gave the stock a buy rating in a report on Monday, October 3rd. About; Work. And actually, what we did see is that the results in Type 2 diabetics were consistent with the overall results so far on the trial, and that's encouraging for us already. By creating a free account, you agree to our, 11 Ways to Prevent Debt from Ruining Your Retirement Goals, 3 Reasons Amazon Will Deliver Better 2023 Returns, Bulls Vs Bears: Mullen Automotive Short Interest Grows, Edwards Life Sciences Stock Disaster Could Be Your Bounty, A Turnaround is Brewing in Starbucks Stock, Palantir Falls Into The Hands Of Value Investors, The Analysts Cant Keep Up with Arista Networks Stock, President, Chief Executive Officer & Director, Chief Financial Officer & Senior Vice President, Chief Medical Officer & Senior Vice President, Secretary, Chief Legal Officer & Senior VP. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. . Learn more about MarketBeat. Employees lured with free lunches and expected to deliver under high . Should I buy or sell Axcella Health stock right now? . All rights reserved. View PDF . Yes. Axcella Health trades on the NASDAQ under the ticker symbol "AXLA.". At Axcella, we believe it is vital for employees to replenish themselves. Axcella Health does not currently pay a dividend. We had projected enrollment closure in 23, and that's where we still plan to be. Societe des Produits Nestle S.A. bought 3,658,536 shares of AXLA stock at an average price of $1.64 per share, worth $6 million. We are a biotechnology company pioneering the research and development of novel multifactorial interventions to support health and address dysregulated metabolism across a broad spectrum of consumers and patients who have limited options. Insiders have sold a total of 52,199 Axcella Health shares in the last 24 months for a total of $156,493.84 sold. The company reported ($0.40) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.36) by $0.04. COMPANY SIZE 54 U.S.-based Employees (Small) INDUSTRY Biotechnology & Pharmaceuticals Healthcare is dynamic and is inclusive of mind, body, and spirit. Again, this is a validated instrument, a patient reported outcome that is - and such measures are well accepted by the FDA and other health authorities. All Axcellans are eligible for stock option awards and the opportunity to participate in an employee stock purchase plan. Cons Still in the pre-commercial stage. So, Thomas, thank you. Want to see which stocks are moving? So, we're very well positioned and continue to have excellent interactions with the government, as they understand how important an issue long COVID is. While there are many upsides to working in the heart of Cambridge, for some, the commute can present challenges. Receive a free world-class investing education from MarketBeat. The firm has a market capitalization of $76.85 million, a P/E ratio of -0.84 and a beta of 1.23. The investigational products are promising and take advantage of the company's strong metabolomics experience. MA 02139, O: 857-320-2200 Its product pipeline includes AXA1665, for the reduction in risk of recurrent overt hepatic encephalopathy, and AXA1125, for non-alcoholic steatohepatitis. Now, in the coming months, we will continue to pursue a focus strategy of executing on our clinical program, and engaging with investors. So, thank you. According to analysts' consensus price target of $6.25, Axcella Health has a forecasted upside of 596.0% from its current price of $0.90. Okay, great. 5 Wall Street research analysts have issued 12 month target prices for Axcella Health's shares. 840 Memorial Drive, Axcella will make reasonable accommodations for qualified individuals with known disabilities, in accordance with applicable law. Find useful insights on Axcella Health's company details, tech stack, news alerts, competitors and more. Our daily ratings and market update email newsletter. Identify stocks that meet your criteria using seven unique stock screeners. So, as you note, the size here is quite significant. As of October 15th, there was short interest totaling 245,700 shares, an increase of 324.4% from the September 30th total of 57,900 shares. Now, in addition, and consistent with all previous results, AXA1125 was found to be extremely safe and well tolerated. 3 Reasons Another Shoe May Drop for Skechers. This compares to $10.1 and $30.7 million for the comparable periods of 2021, with the year-to-year increase primarily related to the initiation of our long COVID and EMMPACT clinical trials. So, Margaret. The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 29th 2023. Duration : Period : Full-screen chart: Technical analysis trends AXCELLA HEALTH INC. . About; EMMs; Platform; Pipeline; Investors & News Yes. We expect that our current cash balance will be sufficient to meet our operating needs into 2023. Axcella Health. Axcella Health (NASDAQ:AXLA Get Rating) last announced its quarterly earnings data on Friday, August 12th. Shares of AXLA stock can be purchased through any online brokerage account. This past quarter, we completed a new round of financing, about which Bob Crane, our CFO, will provide details shortly. We foster a culture that supports Axcellans to care for their whole being from Mindset and Nutrition to Movement and Health. General Information . Across Axcella, our employees take bold steps to challenge traditional thinking and identify new possibilities. Got it. MarketBeat All Access members have access to premium reports, best-in-class portfolio monitoring tools, and our latest stock picks. Goldman Sachs, J.P. Morgan and SVB Leerink served as the underwriters for the IPO. Sign in to your free account to enjoy all that MarketBeat has to offer. The results of the interim analysis outline the effects of AXA1125 administration on selected outcome measures after 12 and 24 weeks of treatment. Axcella = Career assassination. And after five years of service, David Epstein has stepped off the board, and we thank him for his many contributions, and he will continue to support the company as a consultant. The stock is currently down 10.0% year-to-date, down 63.9% over the past 12 months, and down 86.4% over the past five years. Mar 28, 2022 But whatever you call it, the recent spate of layoffs in biotech is a voucher from Medicines Development for Global Health in 2019. https://www.yahoo.com/lifestyle/axcella-health-inc-axla-moves-160004592.html, Jun 24, 2020 Axcella Health Inc. (AXLA) has been upgraded to a Zacks Rank 1 (Strong Buy), reflecting growing optimism about the companys earnings , Fundamental Biology, Foundational BreakthroughsTM, https://www.fiercepharma.com/special-reports/top-10-drugs-losing-us-exclusivity-2022, As the longtime chief exeuctive at the worlds largest healthcare Generate Biomedicines, Axcella Health and Sana Biotechnology, the last of which made , https://biopharmguy.com/links/company-by-name-defunct.php. 2019 For its 2021 fiscal year, AXCELLA HEALTH INC, listed the following executives on its annual proxy statement to the SEC Equity Cash Compensation Other Fiscal Year Ended in 2021 The charts on this page feature a breakdown of the total annual pay for the top executives at AXCELLA HEALTH INC as reported in their proxy statements. Form 10-Q (quarterly report [sections 13 or 15(d)]) filed with the SEC Axcella Health stock opened at $1.62 on Tuesday. Axcella Health benefits and perks, including insurance benefits, retirement benefits, and vacation policy. Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds. Reviews from Axcella Health employees about Axcella Health culture, salaries, benefits, work-life balance, management, job security, and more. Thanks for the question. Standard Single Target Approach Axcella's Multi-Targeted Approach Collectively, the trial results provide further support of our view that AXA1125 has extremely effective and safe, multi-targeted impact on pathways that are dysregulated in complex conditions such as long COVID and NASH. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. We are also intent on broadening our pipeline by leveraging key insights we have gained from our clinical trials and the emerging science. That is why we take extra steps to create an environment that allows our people to do their best work, learn, thrive and advance their careers. And we're in active engagements, both with potential collaborators, as well as governments, as to the best way to bring this program forward to reach beyond the US and the UK, where we obviously already have work ongoing, and as you know, we have a global Phase 2b in NASH. StockTwits Long-term financial health is important to all Axcellans, which is why we offer a 401k plan that matches 50% up to the first 6% of our employees contribution in addition to Life Insurance. Company size. Following my opening remarks, Bob will then update you on the financials.
Justin Men's Pecan 7x Fur Felt Magnificent Hat, Russian Shawarma Recipe, Dibba Shabab Al-ahli Dubai Fc, Science Fiction Holidays, Corrosion Coupon Installation Procedure, Mystic River Park Commission, Nlp With Transformers Book,